2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-168007
    NSC804515
    NSC804515 is a lead compound for ATPase. NSC804515 can be used in cancer and nervous system related research.
    NSC804515
  • HY-168014
    5-Methylthio DMT 5102-11-4
    5-Methylthio DMT (5-OMe DMT) is a tryptamine with psychoactivity.
    5-Methylthio DMT
  • HY-168021
    MAO-A/SERT-IN-1 3001361-38-9
    MAO-A/SERT-IN-1 is an inhibitor of MAO-A/serotonin transporter (SERT). MAO-A/SERT-IN-1 can reduce SERT-mediated reuptake of 5-HT and has neuroprotective effects in cell inhibition models. MAO-A/SERT-IN-1 can improve depressive behavior in zebrafish and mice.
    MAO-A/SERT-IN-1
  • HY-168025
    VU6007496 2127101-85-1
    VU6007496 is a highly selective and CNS penetrant M1 positive allosteric modulator (PAM). VU6007496 shows excellent pharmacokinetics (PK).
    VU6007496
  • HY-168028
    mGluR2 modulator 5 1639898-35-3
    mGluR2 modulator 5 (Compound 11) is an orally active, selective mGluR2 negative allosteric modulator with an IC50 of 8.9 nM. Pharmacokinetic studies in rats show that mGluR2 modulator 5 can effectively cross the blood-brain barrier. It can modulate cognitive and neurological functions in mood disorders and is suitable for research in the field of neurodegenerative diseases.
    mGluR2 modulator 5
  • HY-168031
    AChE/BChE-IN-21 2756368-79-1
    AChE/BChE-IN-21 is a histamine H3 receptor antagonist, calcium channel blocker, and acetylcholinesterase inhibitor. AChE/BChE-IN-21 exhibits neuroprotective activity against H2O2 and Aβ1-40, and can restore cognitive function in AD mice.
    AChE/BChE-IN-21
  • HY-168041
    LRRK2-IN-15
    LRRK2-IN-15 is an LRRK2 inhibitor. The IC50 value for PBMC cells is 5 nM, and the IC50 value for BCRP is 1.5 μM. LRRK2-IN-15 can be used for research on Parkinson's disease.
    LRRK2-IN-15
  • HY-168051
    TLX agonist 2
    TLX agonist 2 (compound 31) is a TLX agonist (EC50=0.1 μM; Kd=0.16 μM). TLX agonist 2 promotes TLX transcriptional activity and enhances the expression of TLX target genes by binding to TLX. TLX agonist 2 can be used in the study of neurodegenerative diseases.
    TLX agonist 2
  • HY-168052
    hAChE-IN-9
    hAChE-IN-9 (compound 7i) is a selective inhibitor of human acetylcholinesterase (hAChE) with IC50 of 0.05 μM and 2.85 μM for AChE and BChE, respectively. hAChE-IN-9 modulates toxic Aβ oligomer forms into non-toxic ones and has antioxidant and neuroprotective effects against Aβ-induced toxicity. hAChE-IN-9 can be used for the study of Alzheimer's disease.
    hAChE-IN-9
  • HY-168060
    (8R)-8-Hydroxyepoxyboetirane A
    (8R)-8-Hydroxyepoxyboetirane A is a neurogenic compound that interacts with PKC δ-C1B. (8R)-8-Hydroxyepoxyboetirane A binds to the PKC enzyme pocket via hydrogen bonds with Gly-253, Leu-251 and Thr242. (8R)-8-Hydroxyepoxyboetirane A induces NRG1 release and differentiation of NSC into neurons. (8R)-8-Hydroxyepoxyboetirane A is promising for research of neurological disorders.
    (8R)-8-Hydroxyepoxyboetirane A
  • HY-168068
    Res-Glu3
    Res-Glu3 is the derivative of Resveratrol (HY-16561). Res-Glu3 mitigates the ROS accumulation, and exhibits neuroprotective efficacy against H2O2-caused cellular damage in PC12. Res-Glu3 exhibits antioxidant activity in rats ischemia reperfusion models.
    Res-Glu3
  • HY-168079
    GSK-3β inhibitor 21
    GSK-3β inhibitor 21 (compound 44) is an ATP-competitive GSK-3β inhibitor (IC50=6.06 μM) with anti-amyloid aggregation and tau phosphorylation inhibitory activities. GSK-3β inhibitor 21 can be used in the study of Alzheimer's disease.
    GSK-3β inhibitor 21
  • HY-168096
    iNOs-IN-5
    iNOs-IN-5 (Compound BN-4) is an inhibitor for iNOS with an IC50 of 0.1707 μM, and reduces NO levels in LPS (HT-D1056)-induced RAW264.7 cells. iNOs-IN-5 reduces the hypoxic injury stimulated ROS and lactate dehydrogenase expression, and exhibits anti-necrosis and anti-apoptosis efficacy. iNOs-IN-5 exhibits anti-cerebral ischemia and neuroprotective activities in SD rat models. iNOs-IN-5 is blood-brain barrier penetrable.
    iNOs-IN-5
  • HY-168167
    BuChE-IN-14 38455-99-1
    BuChE-IN-14 is a novel compound that selectively inhibits acetylcholinesterase (AChE) activity. BuChE-IN-14 showed a concentration-dependent inhibitory effect on AChE in rat brain in vitro experiments. BuChE-IN-14 can increase the extracellular acetylcholine (ACh) concentration in the rat hippocampus and striatum at a certain dose. BuChE-IN-14 may help improve memory impairment caused by cholinergic dysfunction.
    BuChE-IN-14
  • HY-168169
    hMAO-B-IN-10
    hMAO-B-IN-10 (compound 7) is an inhibitor of MAO-A/B with IC50 of 424.1 nM and 177.9 nM, respectively. hMAO-B-IN-10 exerts a certain neuroprotective effect in MPTP (HY-15608)-induced mouse PD model..
    hMAO-B-IN-10
  • HY-168177
    ROS-IN-3
    ROS-IN-3 (compound x38) is a ROS inhibitor. ROS-IN-3 can be used in neuro-related research.
    ROS-IN-3
  • HY-168214
    Kv7.2/Kv7.3 agonist 1 2315450-35-0
    Kv7.2/Kv7.3 agonist 1 (Compound 16) is an orally active agonist for KV7.2/7.3 channel (KCNQ2/3) with an EC50 of 1.03 μM. Kv7.2/Kv7.3 agonist 1 exhibits analgesic efficacy in mice chronic constriction injury (CCI) model and mice Streptozotocin (HY-13753)-induced diabetic peripheral neuropathic pain (DPNP) model, with ED50 of 12.02 and 9.63 mg/kg.
    Kv7.2/Kv7.3 agonist 1
  • HY-168240
    NMDAR antagonist 2
    NMDAR antagonist 2 (compound 3I) is a CNS penetrant NMDAR antagonist with the IC50 of 4.42 μM and 214.75 μM for hGluN1/hGluN2A at −60 mV or 40 mV membrane potentials, respectively. NMDAR antagonist 2 can reduce hippocampal damage.
    NMDAR antagonist 2
  • HY-168264
    MC1
    MC1 is a potent NLRP3 inhibitor with a KD value of 19.3 nM. MC1 shows no cytotoxicity. MC1 ameliorates cognitive deficits without eliciting adverse effects and shows an absence of hepatotoxicity. MC1 has the potential for the research of Alzheimer's disease (AD).
    MC1
  • HY-168273
    Glutaminyl cyclases-IN-2
    Glutaminyl cyclases-IN-2 (compound 27) is a potent inhibitor of glutaminyl cyclase, with the IC50 of 0.08 μM. Glutaminyl cyclases-IN-2 plays an important role in cancer research.
    Glutaminyl cyclases-IN-2
Cat. No. Product Name / Synonyms Application Reactivity